Deciphering the role of antiviral innate immune mechanisms among respiratory viruses

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 504839

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    2024
  • Known Financial Commitments (USD)

    $74,271.6
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    Boivin Guy
  • Research Location

    Canada
  • Lead Research Institution

    CHU de Québec
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Unspecified

Abstract

Multiple respiratory viruses such as influenza and coronaviruses (for instance, the SARS-CoV-2 pandemic virus) can concurrently or sequentially infect the respiratory tract leading to virus-virus interactions. These interactions can be positive (additive or synergistic) or negative (antagonistic). In this research proposal, we will be studying negative interactions, an entity called viral interference. In this case, a first virus reduces the replication of a second virus for a certain period of time and such effect will be assessed at the population level as well as in permissive animal models and human epithelial cells. Furthermore, a first stimulation with virus or a vaccine has been also associated with long term innate non-specific immunity towards an unrelated virus, a phenomena called trained immunity. We hypothesize that a better understanding of the mechanisms involved in innate host resistance may improve mathematical models of transmission predicting epidemic peaks and pandemic waves and lead to the development of novel wide-spectrum prophylactic and therapeutic modalities against respiratory viruses.